Preliminary findings on the use of metadoxine for the treatment of alcohol dependence and alcoholic liver disease

Lorenzo Leggio, George A. Kenna, Anna Ferrulli, William H. Zywiak, Fabio Caputo, Robert M. Swift, Giovanni Addolorato

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Objective Metadoxine is approved in Europe for alcohol intoxication and is also indicated for alcoholic liver disease (ALD). This study aims to investigate the use of metadoxine as a potential pharmacotherapy for alcohol dependence (AD). Methods This is a retrospective study of 94 outpatients with AD, who received metadoxine for alcohol intoxication and were assessed for alcohol consumption, craving [Visual Analog Scale (VAS)] and liver-related and alcohol-related biomarkers [aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl-transpeptidase, mean corpuscular volume]. Results Range of metadoxine dose was 500-2000mg/day, with a mean dose of 1277(s.d.290)mg/day, and for a period of 2-42days, with a mean period of 8.9(s.d.7.0)days. Follow-up data were available for 52 patients (55.3%); 35(67.3%) patients were completely abstinent. There was a significant decrease in drinks per week, even after substituting baseline drinking as follow-up data for dropouts (p

Original languageEnglish
Pages (from-to)554-559
Number of pages6
JournalHuman Psychopharmacology
Volume26
Issue number8
DOIs
Publication statusPublished - Dec 2011

Fingerprint

Alcoholic Liver Diseases
Alcoholism
Alcoholic Intoxication
Erythrocyte Indices
gamma-Glutamyltransferase
Therapeutics
Aspartate Aminotransferases
Alanine Transaminase
Visual Analog Scale
Alcohol Drinking
Drinking
Outpatients
Retrospective Studies
Biomarkers
Alcohols
Drug Therapy
metadoxine
Liver

Keywords

  • alcohol craving
  • alcohol dependence
  • alcoholic liver disease
  • metadoxine

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Neurology
  • Pharmacology (medical)

Cite this

Preliminary findings on the use of metadoxine for the treatment of alcohol dependence and alcoholic liver disease. / Leggio, Lorenzo; Kenna, George A.; Ferrulli, Anna; Zywiak, William H.; Caputo, Fabio; Swift, Robert M.; Addolorato, Giovanni.

In: Human Psychopharmacology, Vol. 26, No. 8, 12.2011, p. 554-559.

Research output: Contribution to journalArticle

Leggio, Lorenzo ; Kenna, George A. ; Ferrulli, Anna ; Zywiak, William H. ; Caputo, Fabio ; Swift, Robert M. ; Addolorato, Giovanni. / Preliminary findings on the use of metadoxine for the treatment of alcohol dependence and alcoholic liver disease. In: Human Psychopharmacology. 2011 ; Vol. 26, No. 8. pp. 554-559.
@article{066e6a4cac1640bbbf451586f91d76e2,
title = "Preliminary findings on the use of metadoxine for the treatment of alcohol dependence and alcoholic liver disease",
abstract = "Objective Metadoxine is approved in Europe for alcohol intoxication and is also indicated for alcoholic liver disease (ALD). This study aims to investigate the use of metadoxine as a potential pharmacotherapy for alcohol dependence (AD). Methods This is a retrospective study of 94 outpatients with AD, who received metadoxine for alcohol intoxication and were assessed for alcohol consumption, craving [Visual Analog Scale (VAS)] and liver-related and alcohol-related biomarkers [aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl-transpeptidase, mean corpuscular volume]. Results Range of metadoxine dose was 500-2000mg/day, with a mean dose of 1277(s.d.290)mg/day, and for a period of 2-42days, with a mean period of 8.9(s.d.7.0)days. Follow-up data were available for 52 patients (55.3{\%}); 35(67.3{\%}) patients were completely abstinent. There was a significant decrease in drinks per week, even after substituting baseline drinking as follow-up data for dropouts (p",
keywords = "alcohol craving, alcohol dependence, alcoholic liver disease, metadoxine",
author = "Lorenzo Leggio and Kenna, {George A.} and Anna Ferrulli and Zywiak, {William H.} and Fabio Caputo and Swift, {Robert M.} and Giovanni Addolorato",
year = "2011",
month = "12",
doi = "10.1002/hup.1244",
language = "English",
volume = "26",
pages = "554--559",
journal = "Human Psychopharmacology",
issn = "0885-6222",
publisher = "John Wiley and Sons Ltd",
number = "8",

}

TY - JOUR

T1 - Preliminary findings on the use of metadoxine for the treatment of alcohol dependence and alcoholic liver disease

AU - Leggio, Lorenzo

AU - Kenna, George A.

AU - Ferrulli, Anna

AU - Zywiak, William H.

AU - Caputo, Fabio

AU - Swift, Robert M.

AU - Addolorato, Giovanni

PY - 2011/12

Y1 - 2011/12

N2 - Objective Metadoxine is approved in Europe for alcohol intoxication and is also indicated for alcoholic liver disease (ALD). This study aims to investigate the use of metadoxine as a potential pharmacotherapy for alcohol dependence (AD). Methods This is a retrospective study of 94 outpatients with AD, who received metadoxine for alcohol intoxication and were assessed for alcohol consumption, craving [Visual Analog Scale (VAS)] and liver-related and alcohol-related biomarkers [aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl-transpeptidase, mean corpuscular volume]. Results Range of metadoxine dose was 500-2000mg/day, with a mean dose of 1277(s.d.290)mg/day, and for a period of 2-42days, with a mean period of 8.9(s.d.7.0)days. Follow-up data were available for 52 patients (55.3%); 35(67.3%) patients were completely abstinent. There was a significant decrease in drinks per week, even after substituting baseline drinking as follow-up data for dropouts (p

AB - Objective Metadoxine is approved in Europe for alcohol intoxication and is also indicated for alcoholic liver disease (ALD). This study aims to investigate the use of metadoxine as a potential pharmacotherapy for alcohol dependence (AD). Methods This is a retrospective study of 94 outpatients with AD, who received metadoxine for alcohol intoxication and were assessed for alcohol consumption, craving [Visual Analog Scale (VAS)] and liver-related and alcohol-related biomarkers [aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl-transpeptidase, mean corpuscular volume]. Results Range of metadoxine dose was 500-2000mg/day, with a mean dose of 1277(s.d.290)mg/day, and for a period of 2-42days, with a mean period of 8.9(s.d.7.0)days. Follow-up data were available for 52 patients (55.3%); 35(67.3%) patients were completely abstinent. There was a significant decrease in drinks per week, even after substituting baseline drinking as follow-up data for dropouts (p

KW - alcohol craving

KW - alcohol dependence

KW - alcoholic liver disease

KW - metadoxine

UR - http://www.scopus.com/inward/record.url?scp=83855161666&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83855161666&partnerID=8YFLogxK

U2 - 10.1002/hup.1244

DO - 10.1002/hup.1244

M3 - Article

VL - 26

SP - 554

EP - 559

JO - Human Psychopharmacology

JF - Human Psychopharmacology

SN - 0885-6222

IS - 8

ER -